Multimodal treatment of resectable pancreatic ductal adenocarcinoma

N Silvestris, O Brunetti, E Vasile, F Cellini, I Cataldo, V Pusceddu, M Cattaneo, S Partelli, M Scartozzi, G Aprile, A Casadei Gardini, AG Morganti, V Valentini, A Scarpa, M Falconi, A Calabrese, V Lorusso, M Reni, S Cascinu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases (chemotherapy) and locoregional failures (chemoradiotherapy). Herein, we provide a critical overview on the role of multimodal treatment in PDAC and on new opportunities related to current more active poli-chemotherapy regimens, targeted therapies, and the more recent immunotherapy approaches. Moreover, an analysis of pathological markers and clinical features able to help clinicians in the selection of the best therapeutic strategy will be discussed. Lastly, the role of neoadjuvant treatment of initially resectable disease will be considered mostly in patients whose malignancy shows morphological but not clinical or biological criteria of resectability. Depending on the results of these investigational studies, today a multidisciplinary approach can offer the best address therapy for these patients. © 2017 Elsevier B.V.
Original languageEnglish
Pages (from-to)152-165
Number of pages14
JournalCritical Reviews in Oncology/Hematology
Volume111
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

Combined Modality Therapy
Adenocarcinoma
Therapeutics
Drug Therapy
Neoadjuvant Therapy
Chemoradiotherapy
Immunotherapy
Biomarkers
Neoplasm Metastasis
Incidence
Neoplasms

Cite this

Silvestris, N., Brunetti, O., Vasile, E., Cellini, F., Cataldo, I., Pusceddu, V., ... Cascinu, S. (2017). Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 111(1), 152-165. https://doi.org/10.1016/j.critrevonc.2017.01.015

Multimodal treatment of resectable pancreatic ductal adenocarcinoma. / Silvestris, N; Brunetti, O; Vasile, E; Cellini, F; Cataldo, I; Pusceddu, V; Cattaneo, M; Partelli, S; Scartozzi, M; Aprile, G; Casadei Gardini, A; Morganti, AG; Valentini, V; Scarpa, A; Falconi, M; Calabrese, A; Lorusso, V; Reni, M; Cascinu, S.

In: Critical Reviews in Oncology/Hematology, Vol. 111, No. 1, 2017, p. 152-165.

Research output: Contribution to journalArticle

Silvestris, N, Brunetti, O, Vasile, E, Cellini, F, Cataldo, I, Pusceddu, V, Cattaneo, M, Partelli, S, Scartozzi, M, Aprile, G, Casadei Gardini, A, Morganti, AG, Valentini, V, Scarpa, A, Falconi, M, Calabrese, A, Lorusso, V, Reni, M & Cascinu, S 2017, 'Multimodal treatment of resectable pancreatic ductal adenocarcinoma', Critical Reviews in Oncology/Hematology, vol. 111, no. 1, pp. 152-165. https://doi.org/10.1016/j.critrevonc.2017.01.015
Silvestris, N ; Brunetti, O ; Vasile, E ; Cellini, F ; Cataldo, I ; Pusceddu, V ; Cattaneo, M ; Partelli, S ; Scartozzi, M ; Aprile, G ; Casadei Gardini, A ; Morganti, AG ; Valentini, V ; Scarpa, A ; Falconi, M ; Calabrese, A ; Lorusso, V ; Reni, M ; Cascinu, S. / Multimodal treatment of resectable pancreatic ductal adenocarcinoma. In: Critical Reviews in Oncology/Hematology. 2017 ; Vol. 111, No. 1. pp. 152-165.
@article{440037c222094d1eb382c48dc358a721,
title = "Multimodal treatment of resectable pancreatic ductal adenocarcinoma",
abstract = "After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases (chemotherapy) and locoregional failures (chemoradiotherapy). Herein, we provide a critical overview on the role of multimodal treatment in PDAC and on new opportunities related to current more active poli-chemotherapy regimens, targeted therapies, and the more recent immunotherapy approaches. Moreover, an analysis of pathological markers and clinical features able to help clinicians in the selection of the best therapeutic strategy will be discussed. Lastly, the role of neoadjuvant treatment of initially resectable disease will be considered mostly in patients whose malignancy shows morphological but not clinical or biological criteria of resectability. Depending on the results of these investigational studies, today a multidisciplinary approach can offer the best address therapy for these patients. {\circledC} 2017 Elsevier B.V.",
author = "N Silvestris and O Brunetti and E Vasile and F Cellini and I Cataldo and V Pusceddu and M Cattaneo and S Partelli and M Scartozzi and G Aprile and {Casadei Gardini}, A and AG Morganti and V Valentini and A Scarpa and M Falconi and A Calabrese and V Lorusso and M Reni and S Cascinu",
year = "2017",
doi = "10.1016/j.critrevonc.2017.01.015",
language = "English",
volume = "111",
pages = "152--165",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Multimodal treatment of resectable pancreatic ductal adenocarcinoma

AU - Silvestris, N

AU - Brunetti, O

AU - Vasile, E

AU - Cellini, F

AU - Cataldo, I

AU - Pusceddu, V

AU - Cattaneo, M

AU - Partelli, S

AU - Scartozzi, M

AU - Aprile, G

AU - Casadei Gardini, A

AU - Morganti, AG

AU - Valentini, V

AU - Scarpa, A

AU - Falconi, M

AU - Calabrese, A

AU - Lorusso, V

AU - Reni, M

AU - Cascinu, S

PY - 2017

Y1 - 2017

N2 - After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases (chemotherapy) and locoregional failures (chemoradiotherapy). Herein, we provide a critical overview on the role of multimodal treatment in PDAC and on new opportunities related to current more active poli-chemotherapy regimens, targeted therapies, and the more recent immunotherapy approaches. Moreover, an analysis of pathological markers and clinical features able to help clinicians in the selection of the best therapeutic strategy will be discussed. Lastly, the role of neoadjuvant treatment of initially resectable disease will be considered mostly in patients whose malignancy shows morphological but not clinical or biological criteria of resectability. Depending on the results of these investigational studies, today a multidisciplinary approach can offer the best address therapy for these patients. © 2017 Elsevier B.V.

AB - After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases (chemotherapy) and locoregional failures (chemoradiotherapy). Herein, we provide a critical overview on the role of multimodal treatment in PDAC and on new opportunities related to current more active poli-chemotherapy regimens, targeted therapies, and the more recent immunotherapy approaches. Moreover, an analysis of pathological markers and clinical features able to help clinicians in the selection of the best therapeutic strategy will be discussed. Lastly, the role of neoadjuvant treatment of initially resectable disease will be considered mostly in patients whose malignancy shows morphological but not clinical or biological criteria of resectability. Depending on the results of these investigational studies, today a multidisciplinary approach can offer the best address therapy for these patients. © 2017 Elsevier B.V.

U2 - 10.1016/j.critrevonc.2017.01.015

DO - 10.1016/j.critrevonc.2017.01.015

M3 - Article

VL - 111

SP - 152

EP - 165

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 1

ER -